New Research Report: Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

Dec. 8, 2009 - PRLog -- This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

* Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector
* Evaluate the impact of Chugai's alliance with Roche, including forecast strong growth for the Genentech-derived mAb portfolio in Japan
* Assess the forecast performance of Actemra, the first monoclonal antibody product to be developed and successfully launched by a Japanese company

Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/catalog/product.aspx?productid=43010&dt=t

ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Financial performance, 2002-14
Chugai: PharmaVitae forecasts at a glance
Strategic insight
The Roche/Genentech/Chugai alliance
Partnership grants Chugai access to leading mAb portfolio
Reliance on mAb portfolio
Chugai dominates the Japanese mAb landscape
Roche/Genentech portfolio to contribute majority of Chugai's forecast growth
Chugai is good strategic fit for Roche's Japanese market expansion
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
Chapter 3 Quarterly news update
Product developments
Deals and alliances
Product deals
Technology deals
M&A activity
Company announcements
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Acquisition of GenProbe in December 1989
Consolidation into the Roche group in October 2002
Divestments since the Roche merger have promoted Rx focus
Current corporate structure
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2002-14
Product analysis
Product analysis, 2002-08
Product analysis, 2008-14
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2008-14
Core analysis, 2008-14
Expiry analysis, 2008-14
Launch/core/expiry configuration, 2008-14
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
Operating cost ratio and profit margin analysis, 2008-14
Operating costs and profit analysis, 2008-14
Chapter 7 Key products and competitors
Key findings
Overview
Oncology
Avastin
Overview
Sales forecast
First-to-market VEGF inhibitor
Indication broadening expected to drive sales
Key competitors
Herceptin
Overview
Sales forecast
What is Herceptin?
Key competition from Tykerb in the long term
Rituxan
Overview
Sales forecast
What is Rituxan?
Indication-broadening to promote sustained sales expansion
Rituxan currently faces little competition and steady sales are anticipated
Neutrogin
Overview
Sales forecast
Internally developed Neutrogin is central to Chugai's historical growth
Biosimilar threat to EU market
Tarceva
Overview
Sales forecast
What is Tarceva?
Key competitors
Hematology
Epogin
Overview
Sales forecast
Kirin's Espo and follow-on Nesp pose key competition
Mircera to become Epogin's follow-on product
Safety concerns around EPO use in some cancer patients
Biosimilar EPOs available in the 5EU
R-744/Mircera
Overview
Sales forecast
R-744/Mircera provides follow-on to Epog

For more information or to purchase this report, go to http://www.fastmr.com/catalog/product.aspx?productid=43010

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.